摘要
目的 探讨维拉帕米 ( Verapamil,VER)对丝裂霉素 ( mitomycin,MMC)耐药逆转作用。方法 利用人宫颈癌 Hela和耐药亚系 Hela/MMC细胞 ,建立人宫颈癌裸鼠异种移植耐药模型。初步研究了 VER对 MMC体内外增效作用。结果 无毒剂量的 VER( 1～ 3mg/L)可显著增加MMC的细胞毒作用且可基本克服 Hela/MMC细胞对 MMC5.0 2倍耐药 ;并可增加 MMC对宫颈癌细胞 DNA合成的抑制 ;同时可提高 MMC对荷瘤裸鼠 Hela/MMC移植瘤的抑制率 ( P<0 .0 1 )。结论 无毒剂量的 VER体内外能基本逆转 Hela/MMC细胞对
Objective To determine the reversion of mitomycin(MMC)resistance by verapamil (VER)in vitro and in vivo.Methods A xenografted mitomycin resistant mice model of cervical cancer was devoleped.The reversion of mitomycin of resistance by VER was detected for human cervical cancar cell(hela)and its resistant subline Hela/MMC in vitro and in vivo.Results nontoxin doses of VER might enhance the cytotoxicity of MMC in Hela and Hela/MMC,could result in almost complete or partial reversion of MMC resisistance of Heia/MMC, 3H TdR incorporation test indicated that VER enhanced the inhibition of DNA synthesis in Hela and Hela/MMC cell. Conclusion VER can overcome mitomycin resistance of Hela/MMC in vitro and in vivo.
出处
《肿瘤防治研究》
CAS
CSCD
2001年第4期278-280,共3页
Cancer Research on Prevention and Treatment
基金
湖北省教委资助课题 (EK980 0 38)
